Overview Summary

Recent months have seen the first iPSC clinical trial in humans, creation of the worlds largest iPSC biobank, major funding awards, a historic challenge to the Yamanaka Patent, a Supreme Court ruling affecting industry patent rights, announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond. Is it worth it to you to get informed about rapidly-evolving market conditions and identify key industry trends that will give you an advantage over your competition?

Report Applications

This global strategic report is produced for:

Management of Stem Cell Product Companies Management of Stem Cell Therapy Companies Stem Cell Industry Investors It is designed to increase your efficiency and effectiveness in:

Commercializing iPSC products, technologies, and therapies Making intelligent investment decisions Launching high-demand products Selling effectively to your client base Increasing revenue Taking market share from your competition

Executive Summary

Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to differentiate into a wide variety of specialized cell types. The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Conditions such as Huntingtons disease, Parkinsons disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage.

Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics.

Key Report Findings

Induced pluripotent stem cells represent one of the most promising research advances within the past decade, making this a valuable report for both executives and investors to use to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends.

Key report findings include:

-Metrics, Timelines, Tables, and Graphs for the iPSC Industry -Trend Rate Data for iPSC Grants, Clinical Trials, and Scientific Publications -Analysis of iPSC Patent Environment, including Key Patents and Patent Trends -Market Segmentation -5-Year Market Size Projections (2015-2019) -Market Size Estimations, by Market Segment -Updates on Crucial iPSC Industry and Technology Trends -Analysis of iPSC Market Leaders, by Market Segment -Geographical Assessment of iPSC Innovation -SWOT Analysis for the iPSC Sector (Strengths, Weaknesses, Opportunities, Threats) -Preferred Species for iPSC Research -Influential Language for Selling to iPSC Scientists -Breakdown of the Marketing Methods, including Exposure and Response Rates -And Much More -End-User Survey of iPSC Scientists

A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as a research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more.

The findings can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

APPENDIX A - Properties and Characteristics of Induced Pluripotent Stem Cells APPENDIX B - iPSC Patents Held by Cellular Dyamics International (Owned by Fujifilm Holdings) APPENDIX C - Current Clinical Trials Involving iPSCs (ClinicalTrialsgov Analysis) APPENDIX D - Full List of iPSC Clinical Trial Sponsors (ClinicalTrialsgov Analysis) APPENDIX E - List of Grants that Contain iPSC Search Terms within the Title (2006 to Present; RePORTer Tool) APPENDIX F - NIH Center for Regenerative Medicine (CRM) iPSC Stem Cell Line - Control, Reporter, & Differentiated Lines

Read this article:
COMPLETE 2015-16 INDUCED PLURIPOTENT STEM CELL INDUSTRY REPORT